Text Size

A Three Day Trial of Azithromycin Plus Chloroquine for the Treatment of Uncomplicated Plasmodium Falciparum Malaria

This study has been completed.
Sponsor:
Information provided by:
Pfizer
ClinicalTrials.gov Identifier:
NCT00282919
First received: January 26, 2006
Last updated: August 12, 2009
Last verified: August 2009
History of Changes
  Purpose

The treatment of symptomatic, uncomplicated malaria caused by P. falciparum in adults.


Condition Intervention Phase
Falciparum Malaria
 Drug: Azithromycin plus chloroquine
 Phase 2

Study Type: Interventional
Study Design: Allocation: Non-Randomized
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Treatment
Official Title: A Phase 2, Open Label, Non-Comparative Trial Of Azithromycin 2000 mg Plus Chloroquine 600 Mg Base Daily For Three Days For The Treatment Of Uncomplicated Plasmodium Falciparum Malaria

Resource links provided by NLM:

MedlinePlus related topics: Malaria
U.S. FDA Resources

Further study details as provided by Pfizer:

Primary Outcome Measures:
  • To confirm the hypothesis that a dose of 2000 mg Azithromycin plus 600 mg chloroquine base each day for three days is highly efficacious for the treatment of symptomatic, uncomplicated P. falciparum. [ Time Frame: For the duration of the study ] [ Designated as safety issue: No ]

Secondary Outcome Measures:
  • Asexual P. falciparum parasite clearance time [ Time Frame: For the duration of the study ] [ Designated as safety issue: No ]
  • Fever clearance time [ Time Frame: For the duration of the study ] [ Designated as safety issue: No ]
  • An assessment of the safety and tolerability of the treatment regimen [ Time Frame: For the duration of the study ] [ Designated as safety issue: No ]
  • % Early Treatment Failures (ETF) [ Time Frame: For the duration of the study ] [ Designated as safety issue: No ]
  • % Late Treatment Failures (LTF) [ Time Frame: For the duration of the study ] [ Designated as safety issue: No ]
  • Resistance as measured by RI, RII, RIII [ Time Frame: For the duration of the study ] [ Designated as safety issue: No ]
  • Clinical cure rates at 3, 7, 28, and 42 days [ Time Frame: at 3, 7, 28, and 42 days ] [ Designated as safety issue: No ]
  • P. falciparum gametocyte absence rate at 7, 14, 21, 28, 35 and 42 days [ Time Frame: 7, 14, 21, 28, 35 and 42 days ] [ Designated as safety issue: No ]
  • Asexual P. falciparum parasite clearance rate at 7, 14, 21, 35 and 42 days [ Time Frame: 7, 14, 21, 35 and 42 days ] [ Designated as safety issue: No ]

Enrollment: 110
Study Start Date: March 2006
Study Completion Date: February 2008
Primary Completion Date: February 2008 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: Azithromycin plus chloroquine
Single Arm, Open label study
 Drug: Azithromycin plus chloroquine
dose of 2000 mg Azithromycin plus 600 mg chloroquine base

  Eligibility

Ages Eligible for Study:   18 Years and older
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Males and females greater then or equal to the age of 18 with uncomplicated, symptomatic malaria as indicated by the presence of blood smears positive for P. falciparum asexual parasitemia between 1000-100,000 parasites/uL and documented fever greater then or equal to 38.5 C/101.3 F rectal or fever greater then or equal to 38 C/100.4 F oral or history of fever as reported by subject within the prior 24 hours.

Exclusion Criteria:

  • Subjects with severe or complicated malaria. Pregnant or breast feeding women.
  Contacts and Locations
Please refer to this study by its ClinicalTrials.gov identifier: NCT00282919

Locations
Colombia
Pfizer Investigational Site
San Andres de Tumaco, Narino, Colombia
India
Pfizer Investigational Site
Bambolim, Goa, India, 403002
Sponsors and Collaborators
Pfizer
Investigators
Study Director: Pfizer CT.gov Call Center Pfizer
  More Information

Additional Information:
To obtain contact information for a study center near you, click here.  This link exits the ClinicalTrials.gov site

No publications provided

Responsible Party: Director, Clinical Trial Disclosure Group, Pfizer, Inc.
ClinicalTrials.gov Identifier: NCT00282919     History of Changes
Other Study ID Numbers: A0661154
Study First Received: January 26, 2006
Last Updated: August 12, 2009
Health Authority: United States: Food and Drug Administration

Additional relevant MeSH terms:
Malaria
Malaria, Falciparum
Protozoan Infections
Parasitic Diseases
Chloroquine
Chloroquine diphosphate
Azithromycin
Amebicides
Antiprotozoal Agents
Antiparasitic Agents
Anti-Infective Agents
Therapeutic Uses
Pharmacologic Actions
Antimalarials
 Antirheumatic Agents
Anti-Inflammatory Agents, Non-Steroidal
Analgesics, Non-Narcotic
Analgesics
Sensory System Agents
Peripheral Nervous System Agents
Physiological Effects of Drugs
Anti-Inflammatory Agents
Filaricides
Antinematodal Agents
Anthelmintics
Central Nervous System Agents
Anti-Bacterial Agents

ClinicalTrials.gov processed this record on May 23, 2013